PHARMACEUTICAL COMPOSITION COMPRISING TOPIRAMATE

Abstract

The present invention relates to a pharmaceutical composition comprising topiramate, and more particularly, to a solid pharmaceutical composition comprising topiramate, a cellulose derivative, a lipid and optional pharmaceutical excipients, wherein the weight ratio of topiramate to the cellulose derivative is 100:10 to 100. The pharmaceutical compositions of the present invention have excellent formulation properties as well. The pharmaceutical compositions of the present invention can be used for monotherapy for patients who are newly diagnosed with epilepsy, or patients who have been previously treated with combination therapy and now for monotherapy. They can also be used for the add-on treatment of partial seizures in adults and children aged 2 to 16 years.

PCT Published Abstract

A solid pharmaceutical composition comprising topiramate and a process for the preparation thereof comprising:a topiramate, a cellulose derivative, a lipid and optionally a pharmaceutical adjuvant, wherein the weight ratio of topiramate to the cellulose derivative is 100:10˜100.

Claims

1-68. (canceled)

69. A solid pharmaceutical composition comprising topiramate, a cellulose derivative, a lipid and optional pharmaceutical excipients; said cellulose derivative comprising hydroxypropylmethylcellulose, said lipid comprising a glyceryl behenate; wherein the weight ratio of topiramate to hydroxypropylmethylcellulose and glyceryl behenate is from 100:15 to 75:15 to 75.

70. The solid pharmaceutical composition according to claim 69, wherein the weight ratio of topiramate to hydroxypropylmethylcellulose is 100:20 to 50, and the weight ratio of topiramate to glyceryl behenate is 100:20 to 50.

71. The solid pharmaceutical composition according to claim 69, wherein said cellulose derivative further comprises a material selected from the group consisting of methylcellulose, ethylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, hydroxyl ethylcellulose, hydroxypropylmethylcellulose and combinations thereof; and/or said lipid substance further comprises a material selected from the group consisting of C16-C22 fatty acid, carnauba wax, C16-C22 fatty acid glyceride, C16-C22 alkyl alcohol, beeswax, Synthetic waxes, hydrogenated vegetable oils and mixtures thereof.

72. The solid pharmaceutical composition according to claim 69, wherein the glyceryl behenate is selected from the group consisting of behenic acid monoglycerides, behenic acid diglycerides, behenic acid triglycerides, and mixtures thereof.

73. The solid pharmaceutical composition according to claim 69, wherein the topiramate accounts for 2 to 75% of the total weight of the solid pharmaceutical composition.

74. The solid pharmaceutical composition according to claim 69, which is one or more selected from the group consisting of a filler, a disintegrant, a binder and a lubricant.

75. The solid pharmaceutical composition according to claim 74, wherein the filler is selected from the group consisting of starch or its derivatives, corn starch, pregelatinized starch, modified starch, cellulose or its derivatives, microcrystalline cellulose, ethyl cellulose, methyl cellulose; carbohydrates, glucose, sucrose, lactose, mannitol, sorbitol; neutral minerals, calcium carbonate, calcium phosphate and combinations thereof; the disintegrant is selected from the group consisting of crosslinked polyvinylpyrrolidone, sodium starch glycolate, croscarmellose sodium, low-substituted hydroxypropylcellulose and combinations thereof; the binder is selected from the group consisting of polyethylene glycol, starch, polyvinylpyrrolidone, hydroxypropylmethylcellulose and the like, and combinations thereof; the lubricant is selected from the group consisting of magnesium stearate, calcium stearate, talc, starch, stearic acid, colloidal silica, and polyethylene glycol.

76. The solid pharmaceutical composition according to claim 69, which is a pharmaceutical dosage form selected from the group consisting of tablets, capsules and mini-tablet in capsules.

77. The solid pharmaceutical composition according to claim 69, which is a coated tablet comprising a coating material of 1% to 6% by weight based on the total weight of the tablet.

78. The solid pharmaceutical composition according to claim 77, wherein said coating material is selected from the group consisting of ethylcellulose, hydroxypropylmethylcellulose and methacrylic acid-alkyl acrylate copolymers.

79. The solid pharmaceutical composition according to claim 77, wherein said coating material is an aqueous dispersion of hydroxypropylmethylcellulose.

80. The solid pharmaceutical composition according to claim 69, which comprises 100 parts by weight of topiramate, 10 to 100 parts by weight of a cellulose derivative, 10 to 100 parts by weight of a lipid substance and 0 to 500 parts by weight of a pharmaceutically acceptable excipients.

81. The solid pharmaceutical composition according to claim 69, which comprises 100 parts by weight of topiramate, 15 to 75 parts by weight of cellulose derivative, 15 to 75 parts by weight of lipid substance and 0 to 250 parts by weight of pharmaceutically acceptable excipient.

82. The solid pharmaceutical composition according to claim 69, which is left at a temperature of 40° C. for 5 months, wherein the increment (%) of impurities 2,3:4,5-di-O-(1-methylethylidene)-β-D-fructose before and after high temperature treatment is less than 70%, for example, 40 to 70%.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0134] The following examples are provided for the purpose of illustration and are not intended to be used in any way and should not be considered as limitations for this invention. A person skilled in the art will recognize the conventional variations and modifications may be made to the following examples without departing from the spirit or scope of the invention.

[0135] In the following examples of the preparation of the composition unless otherwise stated, the tablets or capsules are prepared in a batch size of 10 kg. Each tablet or capsule contains 100 mg of the active ingredient listed as 100 mg of topiramate in the formulation.

[0136] In the following examples of the preparation of the composition, the various materials are milled by passing through the 80 mesh sieve, unless otherwise stated. In the present invention, various glyceryl behenate and other materials used are readily available in the market. In the following tests of the present invention, when glycerol behenate is used, glycerol dibehenate esters conformed to the British Pharmacopoeia or the European Pharmacopoeia of the version 7.0, unless otherwise specified. As described in the standard, it is a mixture of glyceryl monobeheneate, glyceryl dibehenate, glyceryl tribehenate. Unless otherwise stated, the materials used in the examples, especially the API, are all from the same batch.

Test Method Example Section

Test Method Example 1: HPLC Method for Determining the Amount of Active Ingredient

[0137] This test method can be used to test the amount of the active ingredient in the in-process samples, and the final product; the details of the examples are as followed:

[0138] It is determined according to the Chinese Pharmacopoeia of the 2010 edition, section 2, Appendix IA, the high performance liquid chromatography test method;

[0139] The chromatographic conditions and system suitability test:use octyl-bonded silica as a filler; the mobile phase consist of 0.01 mol/L of ammonium acetate solution (adjusted pH to 4.25±0.2 with acetic acid) and acetonitrile (3:1) as mobile phase; the detector is a refractive index detector, the detection temperature and column temperature are 35° C.; theoretical plate numbers for topiramate peak should not be less than 3000;

[0140] The test method:accurately weigh the amount of the test sample (equal to topiramate about 60 mg), transfer to a 200 ml volumetric flask, add acetonitrile-water (1:4) of 100.0 ml accurately, sealed and shake for 1 hour, centrifuged, filter the upper clear liquid with 0.2 μm filter, take the filtrate as the test solution; accurately weigh 60 mg of topiramate reference standard, transfer it to a 200 ml volumetric flask, add acetonitrile-water (1:4) 100.0 ml accurately, sealed and shake to dissolve, as the standard solution; inject 50 μl each from sample and standard solution, respectively, into the liquid chromatograph, record the chromatogram, use external standard method to calculate assay value of C12H21NO8S in sample.

Test Method Example 2: HPLC Method for Determining the Amount of Impurity A in Test Sample

[0141] The method can be used to test the amount of the impurity A in active pharmaceutical ingredient, the in-process samples, and the final product, details are as follows:

[0142] Test method:accurately weigh the amount of the test sample (equal to topiramate about 120 mg), transfer to a 25 ml-volumetric flask, add acetonitrile-water (1:4) mixture 10.0 ml accurately, sealed and shake for 1 hour, then centrifuged, filter the upper clear liquid with a 0.2 μm filter, take the filtrated solution as the test solution;

[0143] Transfer both 1 ml test solution and about 8 mg accurately weighed impurity A reference standard, onto a 200 mL-volumetric flask, add mobile phase to the mark, shake well, then used as the standard solution;

[0144] According to the chromatographic conditions in test method example 1, inject accurately measured of 50 μl of sample and standard solution, respectively, into the liquid chromatograph, adjust the sensitivity of the instrument to ensure that the peak area of the topiramate in the control solution could meet the requirement of correct integration. The chromatogram of the test solution should be recorded for double value of the main peak retention time/The external standard method should be used to calculate the value of impurities A with the peak area. Generally speaking, the value of impurity A in topiramate formulation should be less than 0.7%, as required by a person skilled in the art.

Test Method Example 3: Stability Study

[0145] Various test samples were placed in a sealed aluminum-plastic composite film bag to prevent the inside and outside air exchange. The test samples were then placed in a controlled 40° C. stability chamber for 5 months to perform a routine high temperature accelerated stability test.

[0146] The assay of the topiramate active ingredient in the samples are determined by using method in test method example 1, including samples in 0-month (not processed at 40° C.) and 5-month (processed at 40° C.) (Unit is mg/g which means the amount of topiramate (mg) in 1 g test sample), and using the following formula to calculate the residual value of topiramate (%) after high temperature treatment in each test sample:

The residual assay (%) of topiramate=[assay in 5-month/assay in 0-month]×100%

[0147] The closer to 100% of the above residual assay (%), the more stable the sample is. When the active ingredient is stored for a long time and the content is reduced due to various reasons, the residual assay should be more than 90% after 5 months stored at 40 □ generally. If it is less than 90%, the product is usually considered as unqualified.

[0148] The assay of the impurity A in the samples are determined by using method in test method example 2, including samples in 0 month (not processed at 40° C.) and 5 month (processed at 40° C.). The increase in the amount or increment (%) of impurity A in each test sample are calculated based on the following formula:

The increase in the amount (%) of impurity A=[(assay for impurity A in 5 months−assay for impurity A in 0 month)/assay of impurity A in 0 month)]×100%

[0149] The closer to 0% value of the above increase amount (%) is, the more stable the sample is; and when the increment is greater, it shows more impurity A in sample.

Example 1

Preparation of a Solid Pharmaceutical Combination Comprising Topiramate

[0150] According to Sample Number Ex1-01 to Ex1-11 in the following table 1, eleven blends can be prepared with different content of topiramate, glyceryl behenate and hydroxypropylmethylcellulose (HPMC). The preparation of the mixed sample is as follows: (1) Each ingredients was milled to fine powder which can pass 60 mesh sieve. The topiramate, glyceryl behenate and hydroxypropylmethylcellulose were mixed fully, and then divided equally into 2 portions. One portion of these mixture is encapsulated into capsule and the other portion compressed into tablets.

[0151] The stability of the tablets from the eleven samples was examined by the method described in Test Method Example 3. The remaining topiramate (%) after 5 months and the increment (%) of the impurity Aare calculated, the result is as follows shown on Table 1:

TABLE-US-00001 TABLE 1 glyc- Hydroxy- the eryl propyl the residual increment Sample be- methyl- assay of the of the No. Topiramate henate cellulose topiramate impurity A Ex1-01 100 35 0 87.2% 258%  Ex1-02 100 35 5 95.3% 206%  Ex1-03 100 35 10 95.7% 144%  Ex1-04 100 35 20 98.4% 53% Ex1-05 100 35 30 98.7% 45% Ex1-06 100 35 35 98.4% 47% Ex1-07 100 35 40 97.6% 46% Ex1-08 100 35 50 96.9% 38% Ex1-09 100 35 75 92.4% 45% Ex1-10 100 35 100 88.5% 53% Ex1-11 100 35 200 84.6% 47%

[0152] It has been surprisingly shown that when the topiramate and glyceryl behenate are mixed with more than 20 parts of hydroxypropylmethylcellulose and the mixture were stressed by mimicing the high temperature and long term storage condition, the concentration of the impurity A is less than that in the samples contained less HPMC or no HPMC. The rate of impurity A growth is very slow in the sample containing a small amount of hydroxypropylmethylcellulose and slower in the sample containing no HPMC. However, when the amount of hydroxypropylmethylcellulose is too high, for example, when the relative amount of hydroxypropylmethylcellulose is 75 parts by weight or more, the active ingredient degraded rapidly. Therefore, when 20 to 50 parts by weight of hydroxypropylmethylcellulose is incorporated in the case of 100 parts by weight of topiramate with glyceryl behenate, it is not only possible to maintain stable and high level of the active ingredient during long term storage, but also slow growth of impurity.

[0153] In addition, the tablets and capsules manufactured from the eleven mixed samples of Ex1-01 to Ex1-11 were analyzed. For each formulation, both the assay of topiramate and the increase of impurity A were reproducible (a difference of no more than 2%).

[0154] Comparative Test 11: referring to the formulations of Ex1-04, Ex1-06, Ex1-08 in the Example 1 above, the hydroxypropylmethylcellulose was replaced with the same amount of methylcellulose, hydroxypropylcellulose, or hydroxyethylcellulose, nine samples were obtained and tested in the same manner as in Test Method Example 3 for stability evaluation. The results showed that the assay (%) of topiramate was in the range of 94 to 97%, but the impurity A was increased by more than 180%, between the ranges of 183 to 252%, which indicated that other cellulose derivatives can not inhibit impurity A growth as hydroxypropylmethylcellulose did.

[0155] Comparative Test 12: referring to the formulations of Ex1-04, Ex1-06, Ex1-08 in the Example 1 above, the same amount of active ingredient, the methylcellulose, hydroxypropylcellulose, or hydroxyethylcellulose were added to the formulation, nine samples were obtained and tested in the same manner as in Test Method Example 3. The results showed that the assay of topiramate was in the range of 95 to 98%, and the increment for impurities A was less than 62%, both in the range of 40 to 62%, which indicated that the addition of the above-mentioned cellulose derivatives did not affect the action of HPMC.

Example 2

Preparation of a Solid Pharmaceutical Combination Comprising Topiramate

[0156] According to the table 2, sample number Ex2-01 to Ex2-11, there were eleven blends that were prepared with different content of topiramate, glyceryl behenate, and hydroxypropylmethylcellulose(HPMC). The preparation of the mixed sample was as follows: (1) each material was milled into fine powders that can pass 60 mesh sieves. The formula amount of topiramate, glyceryl behenate and hydroxypropylmethylcellulose were mixed fully to get a powder mixture. Then, the mixture was divided into 2 parts: one part encapsulated into capsule and the other half compressed into tablets.

[0157] The 5-month stability of the tablets manufactured from the eleven samples was evaluated by the method described in Test Method Example 3, and the residual assay (%) of the topiramate and the increment (%) of the impurity A were calculated. The results werelisted as follows in Table 2:

TABLE-US-00002 TABLE 2 glyc- hydroxy- the eryl propyl- the residual increment Sample be- methyl- assay of the of the No. Topiramate henate cellulose topiramate impurity A Ex2-01 100 35 0 89.4% 271%  Ex2-02 100 35 5 94.5% 213%  Ex2-03 100 35 10 96.2% 136%  Ex2-04 100 35 20 98.7% 57% Ex2-05 100 35 30 98.3% 44% Ex2-06 100 35 35 98.5% 48% Ex2-07 100 35 40 97.3% 43% Ex2-08 100 35 50 96.4% 36% Ex2-09 100 35 75 91.6% 43% Ex2-10 100 35 100 89.3% 50% Ex2-11 100 35 200 85.7% 49%

[0158] It has been surprisingly shown that when the topiramate and hydroxypropylmethylcellulose were mixed with equal to or more than 20 parts of glyceryl behenate, the concentration of the impurity A which should be controlled strictly is less, when compared with the mixture contains less or no glyceryl behenate. Hence, the rate of increase of impurity A is slow with a certain amount of glyceryl behenate, far less than samples containing no glyceryl behenate. However, when the amount of glyceryl behenate is too high, for example, when the relative amount of glyceryl behenate is more than 50 parts by weight, the amount of active ingredient decreases rapidly. Therefore, when 20 to 50 parts by weight of glyceryl behenate is incorporated in the mixture of 100 parts by weight of topiramate and in the presence of hydroxypropylmethylcellulose, it is not only possible to maintain a high and stable level of the active ingredient during long-term storage, but also slow impurity growth.

[0159] In addition, the tablets and capsules from the eleven mixed samples of Ex2-01 to Ex2-11 were tested. For each formulation, both topiramate assay and the amount of impurity A were reproducible (a difference was no more than 1.5%).

[0160] Comparative Test 21: referring to the formulation of Ex2-04, Ex2-06, Ex2-08 in the Example 2 above, the glyceryl behenate was replaced with the same amount of stearic acid, carnauba wax, or stearyl alcohol, there were nine samples obtained. Samples were tested in the same manner as in Test Method Example 3 for stability evaluation. The results showed that topiramate assay is in the range of 87 to 95%, but the impurity A is more than 194% increments, all were in the range of 194 to 242%, which indicates that stearic acid and other similar lipids can not inhibit impurity growth as combination of glyceryl behenate and hydroxypropylmethylcellulose did.

[0161] Comparative Test 22: referring to the formulation of Ex2-04, Ex2-06, Ex2-08 in the Example 2 above, the equal amount of stearic acid, carnauba wax, or stearyl alcohol as the active ingredient was additionally added to the formulation, a total of nine samples were obtained and examined as the same manner in Test Method Example 4. The results showed that topiramate assay was in the range of 95 to 98%, and the increment for impurities A was less than 60%, all were within the range of 40 to 60%, which indicated that the addition of the above-mentioned lipids did not affect the effect ofglyceryl behenate.

[0162] Comparative Test 23: Four finished products, the market product of topiramate tablets (Chinese Medicine Registration No. H20020557), the topiramate capsule (named as #444 capsules here in this study) based on the formulation and preparation of example 1-3 shown in the instruction of the patent CN1419444A(99803589.0), the pellets (named as #367 pellets here) based on the formulation and preparation of Example 6 (chapter from 0117 to 0127) shown in the instruction from CN102579367B (201210080716.8) and the tablet (named as #501 tablet here) based on the formulation and preparation of example 4 shown in the instruction from CN103417501A (201210162377.8), were placed at the 40 □ condition for 5 months. The data collected shows that assay of topiramate was within the range of 93.4 to 96.7%, which indicated that although it is acceptable, it was not as effective as the present invention; but the increment of the impurities A was in the range of 154 to 232%, which indicated that these products were far less effective than the present invention to slow the increment of the impurity A.

Example 3

Preparation of a Solid Pharmaceutical Combination Comprising Topiramate

[0163] The pharmaceutical compositions in the present invention were prepared according to the formulation shown in the table 3 below.

TABLE-US-00003 TABLE 3 Ingredient Weight(mg) Topiramate 100 mg Glyceryl behenate 35 mg HPMC Prescribed quantity Microcrystalline cellulose 40 mg Starch 30 mg Sodium starch glycolate 5 mg PVP K30 3 mg Magnesium stearate 2 mg

[0164] Preparation: The ingredients were milled and passed through a 60 mesh sieve. The active pharmaceutical ingredient, glyceryl behenate, and the prescribed amount of hydroxypropylmethylcellulose were mixed evenly. Then, he microcrystalline cellulose and starch were added onto the mixture and mixed evenly. The above mixed powder was wet granulated with a 5% PVP K30 solution as a binder which prepared by using 50% ethanol to get soft material. Then, the wet granules were dried at 50° C. until the moisture content was less than 2.5%. The dry granules were mixed with the disintegrant and the lubricant evenly and divided in to 2 parts: half of the final blended material encapsulated into the hard capsule shell and the other half compressed into tablets.

[0165] According to the formulation in Table 3, hydroxypropylmethylcellulose was mixed with the amounts (parts by weight) of the topiramate and hydroxypropylmethylcellulose described in Sample of No. Ex3-01 to Ex3-07 listed in Table 4 below. Seven samples of tablets and capsules were obtained.

[0166] The stability of these seven samples was tested by the method in Test Method Example 3 for stability evaluation. The residual assay (%) of topiramate and the increment (%) of impurities A after 5 monthswere calculated. The results are shown in Table 4:

TABLE-US-00004 TABLE 4 glyc- the eryl the residual increment Sample be- assay of the of the No. Topiramate henate HPMC topiramate impurity A Ex3-01 100 35 0 83.5% 264%  Ex3-02 100 35 5 87.9% 213%  Ex3-03 100 35 20 96.4% 63% Ex3-04 100 35 35 98.3% 68% Ex3-05 100 35 50 95.9% 54% Ex3-06 100 35 75 91.2% 67% Ex3-07 100 35 100 86.5% 65%

[0167] The results show that even if other conventional excipients were added, these tablets still had a typical correlation with the amount of hydroxypropylmethylcellulose added in both the residual assay (%) of topiramate and the increment (%) of impurity A. Both these two parameters were not acceptable when the samples had less or no HPMC (<20 parts by weight), and when the amount of hydroxypropylmethylcellulose was too high (>50 parts by weight), the active ingredient assay was still not acceptable. When 20 to 50 parts by weight of hydroxypropylmethylcellulose was incorporated with respect to 100 parts by weight of topiramate, not only the active ingredient can be maintained at a high stable level during the long term storage, but also the impurity growth is slow.

Example 4

Preparation of a Solid Pharmaceutical Combination Comprising Topiramate

[0168] The pharmaceutical compositions in the present invention were prepared according to the formulation shown in the table 5 below.

TABLE-US-00005 TABLE 5 Ingredient Weight(mg) Topiramate 100 mg Glyceryl behenate Prescribed quantity HPMC 35 mg Microcrystalline cellulose 40 mg Starch 30 mg Sodium starch glycolate 5 mg PVP K30 3 mg Magnesium stearate 2 mg

[0169] Preparation: The materials were milled and passed through a 60 mesh sieve. The active pharmaceutical ingredient, hydroxypropylmethylcellulose, and the prescribed amount of glyceryl behenate were mixed evenly. Then, microcrystalline cellulose as filler with starch was added and mixed evenly. The above mixed powder is wet granulated with a 5% PVP K30 solution as a binder which prepared by using 50% ethanol to get soft material. Then the wet granules were dried at 50° C. until the moisture content was less than 2.5%. The dry granules were mixed with the disintegrant and the lubricant evenly, and divided in to 2 parts: half of the final blended materials encapsulated into the hard capsule shell and the other half compressed into tablets.

[0170] According to the formulation in Table 6, glyceryl behenate was mixed with the amount of topiramate and glyceryl behenate described in Sample No. Ex4-01 to Ex4-07 listed below, and the seven mixture samples of tablets and capsules were obtained.

[0171] The stability of these seven samples was tested by the method of Test Method Example 4 for stability evaluation. The residual assay (%) of topiramate and the increment (%) of impurities A after 6 months were calculated. The results are shown in Table 6:

TABLE-US-00006 TABLE 6 glyc- the eryl the residual increment Sample be- assay of the of the No. Topiramate henate HPMC topiramate impurity A Ex4-01 100 35 0 93.5% 242%  Ex4-02 100 35 5 94.4% 194%  Ex4-03 100 35 20 96.3% 66% Ex4-04 100 35 35 96.7% 55% Ex4-05 100 35 50 96.3% 59% Ex4-06 100 35 75 92.3% 64% Ex4-07 100 35 100 87.2% 56%

[0172] The results show that even if other conventional excipients were added, these tablets still had a typical correlation with the amount of glyceryl behenate added in both the residual assay (%) of topiramate and the increment (%) of impurity A. Both these two parameters were not acceptable when the samples had less or no HPMC (<20 parts by weight) added, and when the amount of glyceryl behenate was too high (>50 parts by weight), the active ingredient assay was still not acceptable. When 20 to 50 parts by weight of glyceryl behenate was incorporated with respect to 100 parts by weight of topiramate, not only the active ingredient can be maintained at a high stable level during the long term storage, but also the impurity growth is slow.

Example 5

Preparation of a Solid Pharmaceutical Combination Comprising Topiramate

[0173]

TABLE-US-00007 Ingredient Weight(mg) Topiramate 100 mg Glyceryl behenate 35 mg HPMC 35 mg Microcrystalline cellulose (filler) 100 mg PVP(binder, use 50% alcohol to get a solution 5 mg with 5% concentration PVP) Croscarmellose sodium (disintegrant) 8 mg PEG6000(lubricant) 2 mg

[0174] Preparation: The materials were milled and passed through 60 mesh sieve. The active pharmaceutical ingredient, glyceryl behenate, and hydroxypropylmethylcellulose were mixed evenly. Then, the filler was added and mix evenly. The above blend was granulated with binder and dried at 50° C. until the moisture content was less than 2.5%. The granules were remixed with the disintegrant and the lubricant and divided into 2 parts: half of the blend materials encapsulated into the hard capsule shell and the other half compressed into tablets. Half of the compressed tablets was directly sealed and packaged as core tablets; and the other half of tablets were coated with Opadry® 85F20694 with the coating material account for 3% of the total weight of the final tablets.

[0175] The capsules, core tablets and coated tablets obtained in this example were sealed and tested for stability evaluation by the method in Test Method 3. The results showed that the residual assay of topiramate in capsules, core tablets and coated tablets was within the range of 97.3˜98.2%, and the increment of impurity A was within the range of 45˜60%, which indicated that these preparations have good chemical stability.

Example 6

Preparation of a Solid Pharmaceutical Combination Comprising Topiramate

[0176]

TABLE-US-00008 Ingredient Weight(mg) Topiramate 100 mg Glyceryl behenate 20 mg HPMC 50 mg Microcrystalline cellulose (filler) 40 mg Corn starch (filler) 20 mg PEG2000(binder, use water to get a solution with 5 mg 5% concentration PEG2000) Crosslinked Polyvinylpyrrolidone (disintegrant) 8 mg Colloidal silica (lubricant) 2 mg Magnesium stearate (lubricant) 1 mg

[0177] Preparation: The materials were milled and passed through 60 mesh sieve. The active pharmaceutical ingredient, glyceryl behenate, and hydroxypropylmethylcellulose were mixed evenly. Then the filler was added and mixed evenly. The above mixed powder was wet granulated with a binder. Then, the granules were dried at 50° C. until the moisture content was less than 2.5%. The resulting dry granules were mixed with the disintegrant and the lubricant, and divided into 2 parts: half of the blend encapsulated into the hard capsule shell and the other half compressed into tablets. Half of the resulting tablets were directly sealed and packaged as a core tablet and the other half of the tablets were coated with Opadry®85F23452 with the coating material account for 3% of the total weight of the final tablets.

[0178] The capsules, core tablets, and coated tablets obtained in this example were sealed and tested for stability evaluation by the method of Test Method 3. The results showed that assay of topiramate in capsules, core tablets, and coated tablets were in the range of 96.5˜98.2%, and the increment of impurity A were in the range of 45˜55%, which indicated thatthepreparations have good chemical stability.

Example 7

Preparation of a Solid Pharmaceutical Combination Comprising Topiramate

[0179]

TABLE-US-00009 Ingredient Weight(mg) Topiramate 100 mg Glyceryl behenate 50 mg HPMC 20 mg Corn starch(filler) 60 mg Water(binder) Appropriate amount Lowly substituted hydroxypropylcellulose 5 mg (disintegrant) Magnesium stearate (lubricant) 2 mg

[0180] Preparation: The materials were milled and passed through 60 mesh sieve. The active pharmaceutical ingredient, glyceryl behenate, and hydroxypropylmethylcellulose were mixed evenly. Then, the filler was added and mixed evenly. The above mixed powder was wet granulated with a binder. The wet granules were dried at 50° C. until the moisture content was less than 2.5%. The dry granules were mixed with the disintegrant and the lubricant, and divided into 2 parts: half of the material encapsulated into the hard capsule shells and the other half of compressed into tablets. Half of the tablets were then directly sealed and packaged as core tablets; and the other half of the tablets were coated with Opadry®85F32004 with the coating material account for 3% of the total weight of the final tablets.

[0181] The capsules, core tablets, and coated tablets obtained in this example were sealed and tested for stability evaluation by the method of Test Method 3. The results showed that assay of topiramate in capsules, core tablets, and coated tablets were within the range of 96.5˜97.8%, and the increment of impurity A were within the range of 44˜56%, which indicated that these preparations have good chemical stability.

[0182] In addition, referring to the formulation and preparation in the example 7 above, the glyceryl behenate is replaced by an equal amount of glyceryl behenate with monoester content more than 95%, glyceryl behenate with diester content more than 95%, or glyceryl behenate with triglyceride content more than 95%, to obtain three kinds of coated tablets which were numbered as Ex71, Ex72, Ex73 respectively. The three kinds of coated tablets were sealed and tested for stability evaluation according to the method of test method 4. The results showed that the residual assay of topiramate in these three coated tablets were all in the range of 96.6˜97.7%, and the increment of impurity A were all in the range of 43˜55%, which indicated that these preparations have good chemical stability.

Example 8

Investigation of Drug Properties

[0183] The tablets prepared from Ex1-06, Ex2-06, Ex3-04, Ex4-04, Example 5, Example 6, Example 7 were tested for dissolution, using 900 ml of water as the release medium with paddle at 50 rpm. The results showed that the release amount of the active from the tablets were in the range of 15 to 45% at 1 hour, and the release amount were in the range of 30 to 60% at 4 hours, and the release amount were in the range of 50 to 80% at 8 hours, and the release amount were in the range of 70 to 100% at 12 hours. This indicated that the solid pharmaceutical compositions of the present invention were capable of exhibiting sustained release characteristics.

Example 9

A Combination of a Medication That Has a Conventional Release Performance and a Medication That Has a Sustained Release Performance

[0184] Formulation 5a: According to the formulation and preparation of Example 5, the formulation was compressed into a tablet containing topiramate 20 mg and this tablet has a sustained release property.

[0185] Formulation 5b: According to the formulation and preparation of Example 5, glyceryl behenate and hydroxypropylmethylcellulose were not added. The formulation was compressed into tablets containing topiramate 20 mg, and the tablets had an immediate release property. That is, when using 900 ml of water as the release medium and paddling at 50 rpm speed to determine drug dissolution, more than 78% of the drug was released at 45 minutes.

[0186] Four tablets obtained from Formulation 5a and one tablet obtained from Formulation 5b were encapsulated into a hard capsule shell as a solid formulation having the characteristics described in any example of the solid pharmaceutical agents described in the fourth aspect of the present invention.

Example 10

A Combination of a Medication That Has a Conventional Release Property and a Medication That Has a Sustained Release Property

[0187] Formulation 6a: According to the formulation and preparation of Example 6, the formulation was compressed into a tablet containing topiramate 20 mg and this tablet has a sustained release property.

[0188] Formulation 6b: According to the formulation and preparation of Example 6, glyceryl behenate and hydroxypropylmethylcellulose were not added. The formulation was compressed into tablets containing topiramate 20 mg and the tablets had an immediate release property. That is, when using 900 ml of water as the release medium and paddling at 50 rpm speed to determine drug dissolution, more than 73% of the drug was released at 45 minutes.

[0189] Two tablets obtained from Formulation 6a and two tablets obtained from Formulation 6b were encapsulated into a hard capsule shell as a solid formulation having the characteristics described in any one example of the fourth aspect of the present invention.

Example 11

A Combination of a Medication That Had a Conventional Release Performance and a Medication That Had a Delayed Release Performance

[0190] Formulation 7a: According to the formulation and preparation of Example 7, the formulation was compressed into a tablet containing topiramate 20 mg and this tablet has a sustained release property.

[0191] Formulation 7b: According to the formulation and preparation of Example 7, glyceryl behenate and hydroxypropylmethylcellulose were not added. The formulation was compressed into tablets containing topiramate 20 mg, and the tablets had an immediate release property. That is, when using 900 ml of water as the release medium and paddling at 50 rpm speed to determine drug dissolution, more than 78% of the drug was released at 45 minutes.

[0192] The five tablets obtained from Formulation 7a and one tablet obtained from Formulation 7b are encapsulated into a hard capsule shell as a solid formulation having the characteristics described in any example of the solid pharmaceutical agents described in the fourth aspect of the present invention.

[0193] For Examples 9 to 11, the immediate release tablets and the sustained release tablets may be made into pellets, respectively. The pellets of these two release properties may be encapsulated into hard capsule shells in proportion as a solid formulation having the characteristics described in any example of the solid pharmaceutical agents described in the fourth aspect of the present invention.

[0194] In addition, for Examples from 9 to 11, it was also possible to compress the immediate release portion and the sustained release portion into a double layer tablet using a bi-layer tablet press, and similarly obtain a composition having the characteristics described in any example of the solid pharmaceutical agents described in the fourth aspect of the present invention.

INDUSTRY APPLICABILITY

[0195] The present invention provides a pharmaceutical composition comprising topiramate. The topiramate solid pharmaceutical composition of the present invention can be used as monotherapy for patients newly diagnosed with epilepsy or for epilepsy patients who have been previously treated with combination agents, and it can also be used for adult and for children of 2-16 year old as an add-on treatment for partial seizures.